SCHEMBL7604149

SCHEMBL7604149

O=C1CC=CN(c2ccccn2)N1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.50
ALOX5 P09917 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.42
PLD1 Q13393 1/20 0.41
GAA P10253 2/20 0.41
MAPK1 P28482 1/20 0.41
EP300 Q09472 1/20 0.40
KAT2B Q92831 1/20 0.40
PDCD1 Q15116 3/20 0.40
CD274 Q9NZQ7 3/20 0.40
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
PAK4 O96013 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
FYN P06241 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9645383 0.79 KDM4E (0.33) CRBNALOX5ALDH1A1KDM4EHPGD
SCHEMBL9645835 0.75 ALDH1A1 (0.44) CRBNSMN1; SMN2GAAMAPK1ALDH1A1
SCHEMBL15785562 0.74 PLD1 (0.49) CRBNALOX5SMN1; SMN2PLD1GAA
SCHEMBL9645705 0.73 ALOX5 (0.46) CRBNALOX5SMN1; SMN2PLD1GAA
SCHEMBL1977844 0.72 CD274 (0.45) CRBNALOX5SMN1; SMN2PLD1GAA
SCHEMBL9644560 0.69 CYP1A2 (0.52) SMN1; SMN2MAPK1ALDH1A1CYP1A2POLB
SCHEMBL7964509 0.68 CRBN (0.47) CRBNALOX5SMN1; SMN2PLD1GAA
SCHEMBL19062530 0.68 ALOX5 (0.64) CRBNALOX5SMN1; SMN2PLD1GAA
SCHEMBL5449252 0.68 CD274 (0.47) CRBNALOX5SMN1; SMN2PLD1GAA
SCHEMBL2198674 0.67 CRBN (0.63) CRBNALOX5SMN1; SMN2PLD1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020156285-A1 Novel herbicides KUNZ WALTER (CH) 2002-10-24 US disclosed
US-6380134-B1 USED FOR CONTROLLING WEEDS SYNGENTA CROP PROTECTION, INC. 2002-04-30 US disclosed
US-6369002-B1 HETERO IS PYRIMIDINE OR PYRIDAZINE; 1-(3-FLUORO-5-CHLORO PYRIDIN-2-YL)-3-METHYL-4-TRIFLUOROMETHYLPYRIMIDIN-2,6-DIONE SYNGENTA CROP PROPERTIES, INC. 2002-04-09 US disclosed
CN-1301262-A Novel herbicide NOVARTIS AG (CH) 2001-06-27 CN disclosed
CN-1295570-A N-pyriconyl herbicides NOVARTIS AG (CH) 2001-05-16 CN disclosed
EP-1084117-A2 NOVEL HERBICIDES Novartis AG (CH) 2001-03-21 EP disclosed
EP-1076655-A1 N-PYRIDONYL HERBICIDES Novartis AG (CH) 2001-02-21 EP disclosed
EP-1076656-A2 N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES Novartis AG (CH) 2001-02-21 EP disclosed
WO-1999055693-A2 N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES NOVARTIS AG (CH) 1999-11-04 WO disclosed
WO-1999052893-A1 N-PYRIDONYL HERBICIDES NOVARTIS AG (CH) 1999-10-21 WO disclosed
WO-1999052892-A2 NOVEL HERBICIDES NOVARTIS AG (CH) 1999-10-21 WO disclosed
US-5086052-A Antiarthritic, antiallergens, antiinflammatory agents; also for asthma and psoriasis ABBOTT LABORATORIES (US) 1992-02-04 US disclosed
US-4970210-A ENZYME INHIBITORS ABBOTT LABORATORIES (US) 1990-11-13 US disclosed
EP-0299449-A2 Pyridazinone, triazinone and oxapyridazinone lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1989-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156285-A1 Novel herbicides DDT, CBR1, CBR3 CRBN 2647/4885ALOX5 4636/4885SMN1; SMN2 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.